CoChat
Sign Up
Cited by 375Eosinophilic Disorders and SyndromesAsthma and respiratory diseasesImmunodeficiency and Autoimmune Disorders

Cardiovascular Manifestations of Hypereosinophilic Syndromes

Open access
Ogbogu, Princess U., Rosing, Douglas R., Horne, McDonald K.·2007·Immunology and Allergy Clinics of North America
DOI 10.1016/j.iac.2007.07.001PMC PMC2048688
Open this paper in CoChat — free account

Abstract

The hypereosinophilic syndromes (HESs) are characterized by persistent marked eosinophilia (>1500 eosinophils/mm(3)), the absence of a primary cause of eosinophilia (such as parasitic or allergic disease), and evidence of eosinophil-mediated end organ damage. Cardiovascular complications of HES are a major source of morbidity and mortality in these disorders. The most characteristic cardiovascular abnormality in HES is endomyocardial fibrosis. Patients who have an HES also may develop thrombosis, particularly in the cardiac ventricles, but also occasionally in deep veins. Because of the rarity of these disorders, specific guidelines for the management of the cardiac and thrombotic complications of HES are lacking. This article reviews the diagnosis and management of the cardiovascular manifestations of HES.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.iac.2007.07.001

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Approximately 20% to 50% of patients with hypereosinophilic syndrome exhibit inflammation or fibrosis in the heart.

    “Approximately 20% to 50% of patients with hypereosinophilic syndrome exhibit inflammation or fibrosis in the heart”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [201]

    The Background reports that more recent studies put cardiac disease in HES patients at approximately 40–50%, and its Cardiac Pathology discussion describes myocardial eosinophilic infiltration and later fibrosis. It does not give a 20–50% estimate specifically for patients with cardiac inflammation or fibrosis; its frequency estimate is for cardiac disease more broadly. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

  • Over 40% of patients with eosinophilic granulomatosis with polyangiitis experience cardiovascular complications.

    “over 40% of patients with eosinophilic granulomatosis with polyangiitis, also known as ChurgStrauss, experience cardiovascular complications.”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [201]

    The Background’s Differential Diagnosis section says Churg–Strauss syndrome can involve cardiovascular complications. But the Background’s 40–50% estimate applies to patients with hypereosinophilic syndromes, which the paper lists separately from Churg–Strauss syndrome; it does not establish an over-40% rate for Churg–Strauss patients. No page number is available in our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • Eosinophil-related autoimmune disorders are strongly linked to cardiovascular manifestations including myocarditis.

    “eosinophil-related autoimmune disorders are strongly linked to cardiovascular manifestations including myocarditis.”

    From Autoimmune Myocarditis, Old Dogs and New Tricks. (2024) · cites this paper as [201]

    The Background reports that cardiovascular complications are a major source of morbidity and mortality in hypereosinophilic syndromes, and its Differential Diagnosis section identifies eosinophilic endomyocarditis among the cardiac manifestations of Churg–Strauss syndrome. It does not characterize these conditions collectively as autoimmune disorders, so the claim extends beyond the conditions the paper describes. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 97

  1. [1][1].Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975 Jan;54(1):1–27. [PubMed] [Google Scholar]
  2. [2][2].Ommen SR, Seward JB, Tajik AJ. Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Cardiol. 2000 Jul 1;86(1):110–113. doi: 10.1016/s0002-9149(00)00841-9. [DOI] [PubMed] [Google Scholar] · DOI
  3. [4][4].Ginsberg F, Parrillo JE. Eosinophilic myocarditis. Heart Fail Clin. 2005 Oct;1(3):419–429. doi: 10.1016/j.hfc.2005.06.013. [DOI] [PubMed] [Google Scholar] · DOI
  4. [5][5].Cooper LT, Zehr KJ. Biventricular assist device placement and immunosuppression as therapy for necrotizing eosinophilic myocarditis. Nat Clin Pract Cardiovasc Med. 2005 Oct;2(10):544–548. doi: 10.1038/ncpcardio0322. [DOI] [PubMed] [Google Scholar] · DOI
  5. [6][6].Nutman TB, Miller KD, Mulligan M, Ottesen EA. Loa loa infection in temporary residents of endemic regions: recognition of a hyperresponsive syndrome with characteristic clinical manifestations. J Infect Dis. 1986 Jul;154(1):10–18. doi: 10.1093/infdis/154.1.10. [DOI] [PubMed] [Google Scholar] · DOI
  6. [7][7].Hasley PB, Follansbee WP, Coulehan JL. Cardiac manifestations of Churg-Strauss syndrome: report of a case and review of the literature. Am Heart J. 1990 Oct;120(4):996–999. doi: 10.1016/0002-8703(90)90227-o. [DOI] [PubMed] [Google Scholar] · DOI
  7. [8][8].Pela G, Tirabassi G, Pattoneri P, Pavone L, Garini G, Bruschi G. Cardiac involvement in the Churg-Strauss syndrome. Am J Cardiol. 2006 May 15;97(10):1519–1524. doi: 10.1016/j.amjcard.2005.11.088. [DOI] [PubMed] [Google Scholar] · DOI
  8. [9][9].Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet. 2003 Feb 15;361(9357):587–594. doi: 10.1016/S0140-6736(03)12518-4. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  9. [10][10].Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med. 1982 Jul;97(1):78–92. doi: 10.7326/0003-4819-97-1-78. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  10. [11][11].Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994 May 15;83(10):2759–2779. [PubMed] [Google Scholar]
  11. [12][12].Young JD, Peterson CG, Venge P, Cohn ZA. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature. 1986 Jun 5-11;321(6070):613–616. doi: 10.1038/321613a0. [DOI] [PubMed] [Google Scholar] · DOI
  12. [13][13].Tai PC, Ackerman SJ, Spry CJ, Dunnette S, Olsen EG, Gleich GJ. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet. 1987 Mar 21;1(8534):643–647. doi: 10.1016/s0140-6736(87)90412-0. [DOI] [PubMed] [Google Scholar] · DOI
  13. [14][14].Zientek DM, King DL, Dewan SJ, Harford PH, Youman DJ, Hines TR. Hypereosinophilic syndrome with rapid progression of cardiac involvement and early echocardiographic abnormalities. Am Heart J. 1995 Dec;130(6):1295–1298. doi: 10.1016/0002-8703(95)90161-2. [DOI] [PubMed] [Google Scholar] · DOI
  14. [15][15].Hoffman M, Monroe DM., 3rd. A cell-based model of hemostasis. Thromb Haemost. 2001 Jun;85(6):958–965. [PubMed] [Google Scholar]
  15. [16][16].Ruggeri ZM. Platelet interactions with vessel wall components during thrombogenesis. Blood Cells Mol Dis. 2006 Mar-Apr;36(2):145–147. doi: 10.1016/j.bcmd.2005.12.012. [DOI] [PubMed] [Google Scholar] · DOI
  16. [17][17].Wang JG, Mahmud SA, Thompson JA, Geng JG, Key NS, Slungaard A. The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood. 2006 Jan 15;107(2):558–565. doi: 10.1182/blood-2005-05-2152. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  17. [18][18].Moosbauer C, Morgenstern E, Cuvelier SL, et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood. 2007 Feb 1;109(3):995–1002. doi: 10.1182/blood-2006-02-004945. [DOI] [PubMed] [Google Scholar] · DOI
  18. [19][19].Slungaard A, Vercellotti GM, Tran T, Gleich GJ, Key NS. Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease. J Clin Invest. 1993 Apr;91(4):1721–1730. doi: 10.1172/JCI116382. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  19. [20][20].Venge P, Dahl R, Hallgren R. Enhancement of factor XII dependent reactions by eosinophil cationic protein. Thromb Res. 1979;14(45):641–649. doi: 10.1016/0049-3848(79)90119-1. [DOI] [PubMed] [Google Scholar] · DOI
  20. [21][21].Gambacorti Passerini C, Cortellaro M, Cofrancesco E, et al. Possible mechanisms of fibrin deposition in the hypereosinophilic syndrome. Haemostasis. 1989;19(1):32–37. doi: 10.1159/000215886. [DOI] [PubMed] [Google Scholar] · DOI
  21. [22][22].Rohrbach MS, Wheatley CL, Slifman NR, Gleich GJ. Activation of platelets by eosinophil granule proteins. J Exp Med. 1990 Oct 1;172(4):1271–1274. doi: 10.1084/jem.172.4.1271. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  22. [23][23].Salanitri GC. Endomyocardial fibrosis and intracardiac thrombus occurring in idiopathic hypereosinophilic syndrome. AJR Am J Roentgenol. 2005 May;184(5):1432–1433. doi: 10.2214/ajr.184.5.01841432. [DOI] [PubMed] [Google Scholar] · DOI
  23. [24][24].Hendren WG, Jones EL, Smith MD. Aortic and mitral valve replacement in idiopathic hypereosinophilic syndrome. Ann Thorac Surg. 1988 Nov;46(5):570–571. doi: 10.1016/s0003-4975(10)64701-7. [DOI] [PubMed] [Google Scholar] · DOI
  24. [25][25].Spiegel R, Miron D, Fink D, Gavriel H, Horovitz Y. Eosinophilic pericarditis: a rare complication of idiopathic hypereosinophilic syndrome in a child. Pediatr Cardiol. 2004 Nov-Dec;25(6):690–692. doi: 10.1007/s00246-003-0664-3. [DOI] [PubMed] [Google Scholar] · DOI
  25. [26][26].D’Souza MG, Swistel DG, Castro JL, DeRose JJ., Jr. Hypereosinophilic thrombus causing aortic stenosis and myocardial infarction. Ann Thorac Surg. 2003 Nov;76(5):1725–1726. doi: 10.1016/s0003-4975(03)00689-1. [DOI] [PubMed] [Google Scholar] · DOI
  26. [27][27].Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27;348(13):1201–1214. doi: 10.1056/NEJMoa025217. [DOI] [PubMed] [Google Scholar] · DOI
  27. [28][28].Subhash HS, Asishkumar M, Jonathan M. Unusual cardiac manifestation of hypereosinophilic syndrome. Postgrad Med J. 2002 Aug;78(922):490–491. doi: 10.1136/pmj.78.922.490. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  28. [29][29].Shah R, Ananthasubramaniam K. Evaluation of cardiac involvement in hypereosinophilic syndrome: complementary roles of transthoracic, transesophageal, and contrast echocardiography. Echocardiography. 2006 Sep;23(8):689–691. doi: 10.1111/j.1540-8175.2006.00288.x. [DOI] [PubMed] [Google Scholar] · DOI
  29. [30][30].Syed IS, Martinez MW, Feng DL, Glockner JF. Cardiac magnetic resonance imaging of eosinophilic endomyocardial disease. Int J Cardiol. 2007 Mar 29; doi: 10.1016/j.ijcard.2007.01.019. [DOI] [PubMed] [Google Scholar] · DOI
  30. [31][31].Wagner A, Mahrholdt H, Holly TA, et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet. 2003 Feb 1;361(9355):374–379. doi: 10.1016/S0140-6736(03)12389-6. [DOI] [PubMed] [Google Scholar] · DOI
  31. [32][32].Plastiras SC, Economopoulos N, Kelekis NL, Tzelepis GE. Magnetic resonance imaging of the heart in a patient with hypereosinophilic syndrome. Am J Med. 2006 Feb;119(2):130–132. doi: 10.1016/j.amjmed.2005.10.055. [DOI] [PubMed] [Google Scholar] · DOI
  32. [33][33].Puvaneswary M, Joshua F, Ratnarajah S. Idiopathic hypereosinophilic syndrome: magnetic resonance imaging findings in endomyocardial fibrosis. Australas Radiol. 2001 Nov;45(4):524–527. doi: 10.1046/j.1440-1673.2001.00972.x. [DOI] [PubMed] [Google Scholar] · DOI
  33. [34][34].Chandra M, Pettigrew RI, Eley JW, Oshinski JN, Guyton RA. Cine-MRI-aided endomyocardectomy in idiopathic hypereosinophilic syndrome. Ann Thorac Surg. 1996 Dec;62(6):1856–1858. doi: 10.1016/s0003-4975(96)00947-2. [DOI] [PubMed] [Google Scholar] · DOI
  34. [35][35].Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004 Jan 15;103(2):473–478. doi: 10.1182/blood-2003-08-2798. [DOI] [PubMed] [Google Scholar] · DOI
  35. [36][36].Klion AD, Bochner BS, Gleich GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol. 2006 Jun;117(6):1292–1302. doi: 10.1016/j.jaci.2006.02.042. [DOI] [PubMed] [Google Scholar] · DOI
  36. [37][37].Pitini V, Arrigo C, Azzarello D, et al. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes Blood 1Nov200310293456–3457. author reply 3457 [DOI] [PubMed] [Google Scholar]
  37. [38][38].Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003 May 1;101(9):3391–3397. doi: 10.1182/blood-2002-10-3103. [DOI] [PubMed] [Google Scholar] · DOI
  38. [39][39].Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006 Aug;12(8):908–916. doi: 10.1038/nm1446. [DOI] [PubMed] [Google Scholar] · DOI
  39. [40][40].Hatfield A, Owen S, Pilot PR.In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’ Nat Med Jan200713113 author reply 15-16 [DOI] [PubMed] [Google Scholar]
  40. [42][42].Wilson W, Taubert KA, Gewitz M, et al. Quality of Care and Outcomes Research Interdisciplinary Working Group Prevention of Infective Endocarditis. Guidelines From the American Heart Association A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Circulation 19Apr2007 [DOI] [PubMed] [Google Scholar]
  41. [43][43].Boustany CW, Jr., Murphy GW, Hicks GL., Jr. Mitral valve replacement in idiopathic hypereosinophilic syndrome. Ann Thorac Surg. 1991 Jun;51(6):1007–1009. doi: 10.1016/0003-4975(91)91034-s. [DOI] [PubMed] [Google Scholar] · DOI
  42. [44][44].Fuzellier JF, Chapoutot L, Torossian PF. Mitral valve repair in idiopathic hypereosinophilic syndrome. J Heart Valve Dis. 2004 May;13(3):529–531. [PubMed] [Google Scholar]
  43. [45][45].Fuzellier JF, Chapoutot L, Torossian PF, Metz D, Baehrel B. Mitral valve replacement in idiopathic eosinophilic endocarditis without peripheral eosinophilia. J Card Surg. 2005 Sep-Oct;20(5):472–474. doi: 10.1111/j.1540-8191.2005.200460.x. [DOI] [PubMed] [Google Scholar] · DOI
  44. [46][46].Bell JA, Jenkins BS, Webb-Peploe MM. Clinical, haemodynamic, and angiographic findings in Loffler’s eosinophilic endocarditis. Br Heart J. 1976 Jun;38(6):541–548. doi: 10.1136/hrt.38.6.541. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  45. [47][47].Watanabe K, Tournilhac O, Camilleri LF. Recurrent thrombosis of prosthetic mitral valve in idiopathic hypereosinophilic syndrome. J Heart Valve Dis. 2002 May;11(3):447–449. [PubMed] [Google Scholar]
  46. [48][48].Radford DJ, Garlick RB, Pohlner PG. Multiple valvar replacements for hypereosinophilic syndrome. Cardiol Young. 2002 Jan;12(1):67–70. doi: 10.1017/s1047951102000136. [DOI] [PubMed] [Google Scholar] · DOI
  47. [49][49].Korczyk D, Taylor G, McAlistair H, et al. Heart transplantation in a patient with endomyocardial fibrosis due to hypereosinophilic syndrome. Transplantation. 2007 Feb 27;83(4):514–516. doi: 10.1097/01.tp.0000251385.71296.27. [DOI] [PubMed] [Google Scholar] · DOI
  48. [50][50].Solley GO, Maldonado JE, Gleich GJ, et al. Endomyocardiopathy with eosinophilia. Mayo Clin Proc. 1976 Nov;51(11):697–708. [PubMed] [Google Scholar]
  49. [51][51].Moore PM, Harley JB, Fauci AS. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med. 1985 Jan;102(1):109–114. doi: 10.7326/0003-4819-102-1-109. [DOI] [PubMed] [Google Scholar] · DOI
  50. [52][52].Spry CJ, Davies J, Tai PC, Olsen EG, Oakley CM, Goodwin JF. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med. 1983;52(205):1–22. [PubMed] [Google Scholar]
  51. [53][53].Ishii T, Koide O, Hosoda Y, Takahashi R. Hypereosinophilic multiple thrombosis. A proposal of a new designation of disseminated eosinophilic “collagen disease”. Angiology. 1977 Jun;28(6):361–375. doi: 10.1177/000331977702800601. [DOI] [PubMed] [Google Scholar] · DOI
  52. [54][54].Ishii T, Sternby NH, Hosoda Y. Hypereosinophilic multiple thrombosis. Vasa. 1978;7(3):303–308. [PubMed] [Google Scholar]
  53. [55][55].Fitzpatrick JE, Johnson C, Simon P, Owenby J. Cutaneous microthrombi: a histologic clue to the diagnosis of hypereosinophilic syndrome. Am J Dermatopathol. 1987 Oct;9(5):419–422. [PubMed] [Google Scholar]
  54. [56][56].Kanno H, Ouchi N, Sato M, Wada T, Sawai T. Hypereosinophilia with systemic thrombophlebitis. Hum Pathol. 2005 May;36(5):585–589. doi: 10.1016/j.humpath.2005.03.017. [DOI] [PubMed] [Google Scholar] · DOI
  55. [57][57].Funahashi S, Masaki I, Furuyama T. Hypereosinophilic syndrome accompanying gangrene of the toes with peripheral arterial occlusion--a case report. Angiology. 2006 Mar-Apr;57(2):231–234. doi: 10.1177/000331970605700215. [DOI] [PubMed] [Google Scholar] · DOI
  56. [58][58].Elouaer-Blanc L, Zafrani ES, Farcet JP, Saint-Marc Girardin MF, Mathieu D, Dhumeaux D. Hepatic vein obstruction in idiopathic hypereosinophilic syndrome. Arch Intern Med. 1985 Apr;145(4):751–753. [PubMed] [Google Scholar]
  57. [59][59].Valente O, Scarpinella-Bueno MA. Deep venous thrombosis in hypereosinophilic syndrome. Am Fam Physician. 1994 Oct;50(5):921–922. [PubMed] [Google Scholar]
  58. [60][60].Kojima K, Sasaki T. Veno-occlusive disease in hypereosinophilic syndrome. Intern Med. 1995 Dec;34(12):1194–1197. doi: 10.2169/internalmedicine.34.1194. [DOI] [PubMed] [Google Scholar] · DOI
  59. [61][61].Mukai HY, Ninomiya H, Mitsuhashi S, Hasegawa Y, Nagasawa T, Abe T. Thromboembolism in a patient with transient eosinophilia. Ann Hematol. 1996 Feb;72(2):93–95. doi: 10.1007/BF00641316. [DOI] [PubMed] [Google Scholar] · DOI
  60. [62][62].Zylberberg H, Valla D, Viguie F, Casadevall N. Budd-Chiari syndrome associated with 5q deletion and hypereosinophilia. J Clin Gastroenterol. 1996 Jul;23(1):66–68. doi: 10.1097/00004836-199607000-00019. [DOI] [PubMed] [Google Scholar] · DOI
  61. [63][63].Yamada T, Shinohara K, Katsuki K. A case of idiopathic hypereosinophilic syndrome complicated with disseminated intravascular coagulation. Am J Hematol. 1998 Sep;59(1):100–101. doi: 10.1002/(sici)1096-8652(199809)59:1<100::aid-ajh22>3.0.co;2-e. [DOI] [PubMed] [Google Scholar] · DOI
  62. [64][64].Schulman H, Hertzog L, Zirkin H, Hertzanu Y. Cerebral sinovenous thrombosis in the idiopathic hypereosinophilic syndrome in childhood. Pediatr Radiol. Aug 1999;29(8):595–597. doi: 10.1007/s002470050656. [DOI] [PubMed] [Google Scholar] · DOI
  63. [65][65].Kikuchi K, Minami K, Miyakawa H, Ishibashi M. Portal vein thrombosis in hypereosinophilic syndrome. Am J Gastroenterol. 2002 May;97(5):1274–1275. doi: 10.1111/j.1572-0241.2002.05729.x. [DOI] [PubMed] [Google Scholar] · DOI
  64. [66][66].Walker M. Idiopathic hypereosinophilia associated with hepatic vein thrombosis. Arch Intern Med. 1987 Dec;147(12):2220–2221. [PubMed] [Google Scholar]
  65. [67][67].Uemura K, Nakajima M, Yamauchi N, Fukayama M, Yoshida K. Sudden death of a patient with primary hypereosinophilia, colon tumours, and pulmonary emboli. J Clin Pathol. 2004 May;57(5):541–543. doi: 10.1136/jcp.2003.015321. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  66. [68][68].Liapis H, Ho AK, Brown D, Mindel G, Gleich G. Thrombotic microangiopathy associated with the hypereosinophilic syndrome. Kidney Int. 2005 May;67(5):1806–1811. doi: 10.1111/j.1523-1755.2005.00278.x. [DOI] [PubMed] [Google Scholar] · DOI
  67. [69][69].Sakuta R, Tomita Y, Ohashi M, Nagai T, Murakami N. Idiopathic hypereosinophilic syndrome complicated by central sinovenous thrombosis. Brain Dev. 2007 Apr;29(3):182–184. doi: 10.1016/j.braindev.2006.08.004. [DOI] [PubMed] [Google Scholar] · DOI
  68. [70][70].Narayan S, Ezughah F, Standen GR, Pawade J, Kennedy CT. Idiopathic hypereosinophilic syndrome associated with cutaneous infarction and deep venous thrombosis. Br J Dermatol. 2003 Apr;148(4):817–820. doi: 10.1046/j.1365-2133.2003.05309.x. [DOI] [PubMed] [Google Scholar] · DOI
  69. [71][71].Gumruk F, Gurgey A, Altay C. A case of hypereosinophilic syndrome associated with factor V Leiden mutation and thrombosis. Br J Haematol. 1998 Apr;101(1):208–209. doi: 10.1046/j.1365-2141.1998.0703a.x. [DOI] [PubMed] [Google Scholar] · DOI
  70. [72][72].Johnston AM, Woodcock BE. Acute aortic thrombosis despite anticoagulant therapy in idiopathic hypereosinophilic syndrome. J R Soc Med. 1998 Sep;91(9):492–493. doi: 10.1177/014107689809100912. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  71. [73][73].Harley JB, Fauci AS, Gralnick HR. Noncardiovascular findings associated with heart disease in the idiopathic hypereosinophilic syndrome. Am J Cardiol. 1983 Aug;52(3):321–324. doi: 10.1016/0002-9149(83)90131-5. [DOI] [PubMed] [Google Scholar] · DOI
  72. [74][74].Tanaka H, Kawai H, Tatsumi K, et al. Surgical treatment for Loffler’s endocarditis with left ventricular thrombus and severe mitral regurgitation: a case report. J Cardiol. 2006 Apr;47(4):207–213. [PubMed] [Google Scholar]
  73. [75][75].Hanowell ST, Kim YD, Rattan V, MacNamara TE. Increased heparin requirement with hypereosinophilic syndrome. Anesthesiology. 1981 Oct;55(4):450–452. doi: 10.1097/00000542-198110000-00020. [DOI] [PubMed] [Google Scholar] · DOI
  74. [76][76].Vaitkus PT, Barnathan ES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. J Am Coll Cardiol. 1993 Oct;22(4):1004–1009. doi: 10.1016/0735-1097(93)90409-t. [DOI] [PubMed] [Google Scholar] · DOI
  75. [77][77].Friedman MJ, Carlson K, Marcus FI, Woolfenden JM. Clinical correlations in patients with acute myocardial infarction and left ventricular thrombus detected by two-dimensional echocardiography. Am J Med. 1982 Jun;72(6):894–898. doi: 10.1016/0002-9343(82)90848-8. [DOI] [PubMed] [Google Scholar] · DOI
  76. [78][78].Visser CA, Kan G, Lie KI, Durrer D. Left ventricular thrombus following acute myocardial infarction: a prospective serial echocardiographic study of 96 patients. Eur Heart J. 1983 May;4(5):333–337. doi: 10.1093/oxfordjournals.eurheartj.a061470. [DOI] [PubMed] [Google Scholar] · DOI
  77. [79][79].Gueret P, Dubourg O, Ferrier A, Farcot JC, Rigaud M, Bourdarias JP. Effects of full-dose heparin anticoagulation on the development of left ventricular thrombosis in acute transmural myocardial infarction. J Am Coll Cardiol. 1986 Aug;8(2):419–426. doi: 10.1016/s0735-1097(86)80061-4. [DOI] [PubMed] [Google Scholar] · DOI
  78. [80][80].Davis MJ, Ireland MA. Effect of early anticoagulation on the frequency of left ventricular thrombi after anterior wall acute myocardial infarction. Am J Cardiol. 1986 Jun 1;57(15):1244–1247. doi: 10.1016/0002-9149(86)90196-7. [DOI] [PubMed] [Google Scholar] · DOI
  79. [81][81].Turpie AG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med. 1989 Feb 9;320(6):352–357. doi: 10.1056/NEJM198902093200604. [DOI] [PubMed] [Google Scholar] · DOI
  80. [82][82].Nihoyannopoulos P, Smith GC, Maseri A, Foale RA. The natural history of left ventricular thrombus in myocardial infarction: a rationale in support of masterly inactivity. J Am Coll Cardiol. 1989 Oct;14(4):903–911. doi: 10.1016/0735-1097(89)90463-4. [DOI] [PubMed] [Google Scholar] · DOI
  81. [83][83].Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. Jama. 1999 Dec 1;282(21):2058–2067. doi: 10.1001/jama.282.21.2058. [DOI] [PubMed] [Google Scholar] · DOI
  82. [84][84].Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002 Sep 26;347(13):969–974. doi: 10.1056/NEJMoa020496. [DOI] [PubMed] [Google Scholar] · DOI
  83. [88][88].Brandjes DP, Heijboer H, Buller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992 Nov 19;327(21):1485–1489. doi: 10.1056/NEJM199211193272103. [DOI] [PubMed] [Google Scholar] · DOI
  84. [89][89].Deykin D. Warfarin therapy. 1. N Engl J Med. 1970 Sep 24;283(13):691–694. doi: 10.1056/NEJM197009242831307. [DOI] [PubMed] [Google Scholar] · DOI
  85. [90][90].Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):188S–203S. doi: 10.1378/chest.126.3_suppl.188S. [DOI] [PubMed] [Google Scholar] · DOI
  86. [91][91].Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006 May 2;144(9):673–684. doi: 10.7326/0003-4819-144-9-200605020-00011. [DOI] [PubMed] [Google Scholar] · DOI
  87. [92][92].Priglinger U, Delle Karth G, Geppert A, et al. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill? Crit Care Med. 2003 May;31(5):1405–1409. doi: 10.1097/01.CCM.0000059725.60509.A0. [DOI] [PubMed] [Google Scholar] · DOI
  88. [93][93].Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood. 1991 Nov 1;78(9):2337–2343. [PubMed] [Google Scholar]
  89. [94][94].Zidane M, Schram MT, Planken EW, et al. Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism: a study in routine clinical practice. Arch Intern Med. 2000 Aug 14-28;160(15):2369–2373. doi: 10.1001/archinte.160.15.2369. [DOI] [PubMed] [Google Scholar] · DOI
  90. [95][95].Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993 Sep;95(3):315–328. doi: 10.1016/0002-9343(93)90285-w. [DOI] [PubMed] [Google Scholar] · DOI
  91. [96][96].Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) Italian Study on Complications of Oral Anticoagulant Therapy. 1996 Lancet Aug;348(9025):423–428. doi: 10.1016/s0140-6736(96)01109-9. [DOI] [PubMed] [Google Scholar] · DOI
  92. [97][97].Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998 Aug;105(2):91–99. doi: 10.1016/s0002-9343(98)00198-3. [DOI] [PubMed] [Google Scholar] · DOI
  93. [98][98].Buresly K, Eisenberg MJ, Zhang X, Pilote L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med. 2005 Apr 11;165(7):784–789. doi: 10.1001/archinte.165.7.784. [DOI] [PubMed] [Google Scholar] · DOI
  94. [99][99].Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994 Jun 1;120(11):897–902. doi: 10.7326/0003-4819-120-11-199406010-00001. [DOI] [PubMed] [Google Scholar] · DOI
  95. [101][101].Turpie AG, Gent M, Laupacis A, et al. A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med. 1993 Aug 19;329(8):524–529. doi: 10.1056/NEJM199308193290802. [DOI] [PubMed] [Google Scholar] · DOI
  96. [102][102].Anderson FA, Jr., Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003 Jun 17;107(23 Suppl 1):I9–16. doi: 10.1161/01.CIR.0000078469.07362.E6. [DOI] [PubMed] [Google Scholar] · DOI
  97. [103][103].Kearon C. Duration of therapy for acute venous thromboembolism. Clin Chest Med. 2003 Mar;24(1):63–72. doi: 10.1016/s0272-5231(02)00076-x. [DOI] [PubMed] [Google Scholar] · DOI

Cited by

Sorted by citations

Authors
Ogbogu, P. U., Rosing, D. R., & Horne, M. K.
Affiliations
National Institutes of Health (US)
Corresponding author
Ogbogu, Princess U.
Venue
Immunology and Allergy Clinics of North America
Publisher
Elsevier BV
Published
2007-08
Volume
27
Issue
3
Pages
457-475
ISSN
0889-8561 (ISSN-L)
DOI
10.1016/j.iac.2007.07.001
PMC
PMC2048688
OpenAlex
W2007976042
Cited by
375
References
6
Citations by year
2026: 17 · 2025: 29 · 2024: 33 · 2023: 24 · 2022: 38 · 2021: 20 · 2020: 19 · 2019: 22 · 2018: 14 · 2017: 19 · 2016: 11 · 2015: 25 · 2014: 14 · 2013: 20 · 2012: 25
FWCI
1.54
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Immunology and Allergy Clinics of North America (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institutes of Health (NIH0012170418)
Topics
  • Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
  • Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
  • Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Keywords
hypereosinophilic syndrome, cardiovascular manifestations, endomyocardial fibrosis, cardiac thrombosis, deep vein thrombosis, eosinophilia, diagnosis
MeSH terms
Coronary Thrombosis, Diagnosis, Differential, Heart Diseases, Humans, Cytokines, Hypereosinophilic Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review